All In Biotech

Drug Trial Radar · NCT02600429

Assessment of the Safety and Efficacy Study of RGN-259 Ophthalmic Solutions for Neurotrophic Keratopathy : SEER-1

Phase 3, Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solution for the Treatment of Neurotrophic Keratopathy: SEER-1

Last checked: Nov 19, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

18

Actual

Start

Sep 17, 2015

Primary completion

Nov 20, 2019

Study completion Mar 9, 2020

Sponsor

Lead sponsor
ReGenTree, LLCIndustry
Sponsor type
Industry
First posted
Nov 9, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this study is to assess the safety and efficacy of RGN-259 Ophthalmic Solution compared to placebo for the treatment of NK.

Conditions

  • Neurotrophic Keratopathy

Interventions

  • RGN-259Drug

    A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.

  • PlaceboDrug

    It is composed of the same excipients as RGN-259 but does not contain Tβ4

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Subjects Achieving Complete Healing at Day 29.Time frame: 29 days after first dosing

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Hull Eye Center

    Lancaster, California

  • Vision Institute

    Colorado Springs, Colorado

  • Eye Center of Northern Colorado

    Fort Collins, Colorado

  • Insight Vision Group

    Parker, Colorado

  • Medical Faculty Associates, Inc.

    Washington D.C., District of Columbia

  • Midwest Cornea Associates, LLC

    Indianapolis, Indiana

  • Koffler Vision Group

    Lexington, Kentucky

  • Richard Eiferman, MD, PSC

    Louisville, Kentucky

  • The Eye Care Institute

    Louisville, Kentucky

  • Central Maine Eye Care

    Lewiston, Maine

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.